Press Release Details

View all news

Quest Diagnostics Appoints Robert E. Peters Vice President, Sales and Marketing

03/25/3

TETERBORO, N.J., Mar 25, 2003 /PRNewswire-FirstCall via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that Robert E. Peters has been appointed Vice President, Sales and Marketing.

Mr. Peters will be responsible for leading Sales and Marketing initiatives driving overall profitable growth through ensuring a comprehensive focus on meeting the needs of customers.

In 2002, Mr. Peters was named Regional Vice President, East Region. Previously, he led the company's New York / New Jersey operations.

Prior to joining Quest Diagnostics in 1997, Mr. Peters held a variety of sales leadership and general management positions at Ciba-Geigy AG (now part of Novartis) during a period spanning more than twenty years. He eventually held the position of Vice President, U.S. Operations for the Pharmaceutical Business. Mr. Peters holds a B.S. Degree from North Carolina State University and an MBA from Wake Forest University.

Quest Diagnostics Incorporated is the nation's leading provider of diagnostic testing, information and services, providing insights that enable healthcare professionals to make decisions that improve health. The company offers the broadest access to diagnostic testing services in the United States through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is the leading provider of esoteric testing, including gene-based medical testing, and also empowers healthcare organizations and clinicians with state-of-the-art connectivity solutions that improve patient care. Additional company information is available at: www.questdiagnostics.com.

The statements in this press release which are not historical facts or information may be forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results and outcomes to be materially different. Certain of these risks and uncertainties may include, but are not limited to, unanticipated expenditures, changing relationships with customers, suppliers and strategic partners, conditions of the economy and other factors described in the Quest Diagnostics Incorporated 2002 Form 10-K and subsequent filings.

SOURCE Quest Diagnostics Incorporated

CONTACT:
Investors - Laure Park, +1-201-393-5030, or Media - Gary
Samuels, +1-201-393-5700, both of Quest Diagnostics Incorporated

URL: http://www.questdiagnostics.com

Copyright (C) 2003 PR Newswire. All rights reserved.

Categories: Press Releases
View all news